Skip to main content

Poteligeo Disease Interactions

There is 1 disease interaction with Poteligeo (mogamulizumab).

Moderate

Mogamulizumab (applies to Poteligeo) autoimmune disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder

Fatal and life-threatening immune-mediated complications have been reported in recipients of mogamulizumab. Grade 3 or higher immune-mediated or possibly immune-mediated reactions have included myositis, myocarditis, polymyositis, hepatitis, pneumonitis, and a variant of Guillain- Barré syndrome. Interrupt or permanently discontinue therapy as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of using mogamulizumab in patients with a history of autoimmune disease.

References

  1. (2018) "Product Information. Poteligeo (mogamulizumab)." Kyowa Kirin, Inc

Poteligeo drug interactions

There are 161 drug interactions with Poteligeo (mogamulizumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer